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Summary
Citrate, a central component of cellular metabolism, is a widely used anti-
coagulant due to its ability to chelate calcium. Adenosine triphosphate
(ATP)-citrate lyase, which metabolizes citrate, has been shown to be
essential for inflammation, but the ability of exogenous citrate to impact
inflammatory signalling cascades remains largely unknown. We
hypothesized that citrate would modulate inflammatory responses as both
a cellular metabolite and calcium chelator, and tested this hypothesis by
determining how clinically relevant levels of citrate modulate monocyte
proinflammatory responses to lipopolysaccharide (LPS) in a human acute
monocytic leukaemia cell line (THP-1). In normal medium (04 mM
calcium), citrate inhibited LPS-induced tumour necrosis factor (TNF)-a
and interleukin (IL)-8 transcripts, whereas in medium supplemented with
calcium (14 mM), TNF-a and IL-8 levels increased and appeared
independent of calcium chelation. Using an IL-8–luciferase plasmid
construct, the same increased response was observed in the activation of
the IL-8 promoter region, suggesting transcriptional regulation.
Tricarballylic acid, an inhibitor of ATP-citrate lyase, blocked the ability of
citrate to augment TNF-a, linking citrate’s augmentation effect with its
metabolism by ATP-citrate lyase. In the presence of citrate, increased
histone acetylation was observed in the TNF-a and IL-8 promoter regions
of THP-1 cells. We observed that citrate can both augment and inhibit
proinflammatory cytokine production via modulation of inflammatory
gene transactivation. These findings suggest that citrate anti-coagulation
may alter immune function through complex interactions with the
inflammatory response.
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Introduction
Citrate anti-coagulation is central to the storage of blood
products for transfusion and to maintain the patency of
extracorporeal circuits such as continuous renal replace-
ment therapy (CRRT), used to treat renal failure [1–3].
Citrate prevents activation of the clotting cascade by che-
lating free extracellular calcium, which is a necessary co-
factor for many steps in the coagulation cascade [4].
When used with CRRT, regional anti-coagulation with
citrate lowers ionized calcium concentrations from
12 mM in the patient down to 04 mM in the circuit
[5]. However, plasma citrate concentrations increase from
01 mM prior to initiating CRRT to 4–6 mM within the
circuit and 03–10 mM in the patient after initiation of
the CRRT circuit [5]. In order to prevent the develop-
ment of complications (e.g. citrate ‘lock’), the increased
citrate load delivered as a result of CRRT must be metab-
olized [6]. None the less, the use of citrate for regional
anticoagulation in CRRT results in longer circuit lifetimes,
fewer bleeding complications and possibly increased
patient survival [6–10].
In normal states, citrate is metabolized within the
mitochondria as part of the citric acid cycle or by adeno-
sine triphosphate (ATP)-citrate lyase (ACLY) in the cyto-
plasm for fatty acid synthesis [11,12]. However, recent
studies on immune cells suggest that citrate may play a
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larger role beyond simply energy production. The mito-
chondrial citrate carrier, a transport protein that facili-
tates the efflux of citrate from the mitochondrial matrix
into the cytosol, has been shown to promote immune cell
activation in response to lipopolysaccharide (LPS)
[13,14]. Once outside the mitochondria, ACLY metabo-
lizes citrate into acetyl-CoA and oxaloacetate, which can
be used in the generation of prostaglandins and reactive
oxygen species, respectively [13–16]. Indeed, acetyl-CoA
has often been associated with fatty acid synthesis; how-
ever, it can also be utilized as an acetyl-donor for histone
acetylation [15,17,18]. An increase in histone acetylation
could have a significant impact on the inflammatory
response as there is accumulating evidence that this post-
translational epigenetic modification alters gene expres-
sion patterns [19]. To date, the ability of metabolic inter-
mediates, and specifically exogenously added metabolites
such as citrate, to regulate or alter immune responses has
garnered little attention.
Here, we investigate the impact of externally added
citrate on the monocyte inflammatory response following
LPS-induced immune activation. LPS, a component of
Gram-negative bacterial cell walls, is a potent activator of
innate immune cells leading to the production of pro-
inflammatory cytokines [20]. Monocytes, orchestrators of
the innate inflammatory response, are dependent upon
the opening of cell surface calcium-channels in order to
recognize and respond to pathogens and their endotoxins
[21]. LPS binds to Toll-like receptor 4 on the surface of
monocytes and macrophages, initiating a calcium-
dependent signal transduction cascade leading to nuclear
factor-jB (NF-jB) activation [22–24]. Once translocated
to the nucleus, NF-jB is then able to induce the produc-
tion of various proinflammatory cytokines such as
tumour necrosis factor (TNF)-a and interleukin (IL)-8
[25]. Given the calcium-dependent nature of monocyte
activation induced by LPS, as well as the importance of
energy metabolism during inflammation, we sought to
characterize the impact of citrate on proinflammatory
cytokine responses.
Materials and methods
Chemicals
All chemicals and reagents including sodium citrate and
tricarballylic acid (TCA) were obtained from Sigma-
Aldrich (St Louis, MO, USA) unless noted otherwise.
Cell culture and experimental setup
Human acute monocytic leukaemia cell line (THP-1)
monocytic cells were obtained from ATCC (American
Type Culture Collection, Manassas, VA, USA) [26]. Cells
were maintained in RPMI-1640 complete growth medium
(ATCC) supplemented with 10% heat-inactivated fetal
bovine serum (FBS) (Life Technologies, Grand Island, NY,
USA) and Kanamycin solution from Streptomyces kana-
myceticus [26]. Prior to experiments, THP-1 cells were
rested overnight in medium containing 05% FBS. On the
day of the experiment, cells were resuspended in fresh
medium containing 05% FBS for 30 min. Experiments
were performed in either standard tissue culture medium
which contained 04 mM or a supplemented calcium
medium in which an additional 1 mM CaCl2 was added
to bring the total calcium concentration to 14 mM. Cells
were then pretreated (30 min) with varying concentra-
tions of sodium citrate (1, 6 mM), ethylene glycol-bis(2-
aminoethylether)-N,N,N0,N0-tetraacetic acid [ethylene gly-
col tetraacetic acid (EGTA)], 005–5 mM), or TCA
(1–6 mM) at pH 74, prior to stimulation with LPS
(Escherichia coli O55:B5, 100 ng/ml).
TNF-a protein measurement
Tissue culture supernatants were collected and TNF-a
protein concentration was determined by enzyme-linked
immunosorbent assay (ELISA) using a TNF-a human
antibody pair (Life Technologies, Carlsbad, CA, USA),
according to the manufacturer’s instructions.
Quantitative real-time polymerase chain reaction
(qPCR)
Total RNAs were extracted from cultured cells using TRI-
ZOL reagent (Life Technologies). Template cDNAs were
obtained by reverse transcription (RT) using SuperScript
III Reverse Transcriptase (Invitrogen, Carlsbad, CA,
USA), according to the manufacturer’s instructions.
Quantification of cDNAs was performed by real-time
PCR using primers designed for candidate transcript
detection (Life Technologies). Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH): forward: 50-GTGGAA
GGACTCATGACCACA-30, reverse: 50-GGTTTTTCTAGA
CGGCAGGTC-30; TNF-a: forward: 50-CCAGGCAGTCAG
ATCATCTTC-30, reverse: 50-ATGAGGTACAGGCCCTC
TGAT-30; and IL-8: forward: 50-AGCTCTGTGTGAAGG
TGCAG-30, reverse: 50-AATTTCTGTGTTGGCGCAGT-30.
Real-time polymerase chain reaction (PCR) experiments
were performed in triplicate using SYBR Green chemistry
(Life Technologies) and a Mastercycler ep gradient S
(Eppendorf, Hamburg, Germany). The quantity in each
sample was normalized to the level of reference gene
GAPDH transcripts. Real-time PCR data were analysed by
the delta-delta CT method [27].
Plasmid vectors
The 2162/144 fragment of the full-length human IL-8
promoter, subcloned into luciferase (2162/144hIL-8/
Luc) [28], was provided by M. Hershenson (University of
Michigan, Ann Arbor, MI, USA). The reporter activities
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of this plasmid have been shown to be identical to the
full-length promoter in response to various inflammatory
stimuli [28–30].
Luciferase activity
THP-1 cells were transfected transiently with IL-8-luc
constructs using the 4D-Nucleofector system (Lonza,
Basel, Switzerland) as per the manufacturer’s protocol.
Following transfection, cells were rested (30 min) in
medium (05% FBS) and incubated with citrate (30 min)
prior to LPS stimulation (4 h). Whole cell lysates were
prepared in Reporter Lysis Buffer (Promega, Madison,
WI, USA), following the manufacturer’s protocol. Lucifer-
ase activity was determined using a Luciferase Assay Sys-
tem (Promega) and a Spectramax M3 spectrophotometer
(Molecular Devices, Sunnyvale, CA, USA).
Preparation of histones
Histones were isolated from THP-1 cells using an acid-
extraction technique. Briefly, cells (106) were harvested
following stimulation and washed twice with ice-cold
phosphate buffered saline (PBS) supplemented with
10 mM sodium butyrate. Cells were resuspended in lysis
buffer [PBS containing 05% Triton X 100 (v/v),
01 mM phenylmethysulphonyl fluoride, 10 mM sodium
butyrate, and a protease inhibitor tablet (Roche, Basel,
Switzerland)]. Cells were lysed on ice for 10 min with
gentle stirring and centrifuged at 500 g for 10 min at
4C. The supernatant was discarded and cells were
washed in lysis buffer. The supernatant was again dis-
carded and the pellet was resuspended in 02 N HCl
overnight at 4C. Following acid extraction, 1/5 volume
of 1 M NaOH was added to neutralize extraction and
samples were centrifuged at 500 g for 10 min at 4C.
The supernatant was retained and protein concentration
determined by a Bradford Assay (Thermo Scientific,
Waltham, MA, USA).
Western blot analysis
Acid extracted histones were separated by sodium dodecyl
sulphate reducing polyacrylamide gel electrophoresis
(SDS-PAGE). Total histones were determined by Coomas-
sie stain (ThermoFisher Scientific, Waltham, MA, USA)
as an extraction control or transferred to polyvinylidene
difluoride membranes, as described previously [31]. The
membranes were incubated with primary antibodies for
proteins of interest, including anti-acetyl-Histone H3 (06-
599; Millipore, Billerica, MA, USA) and anti-acetyl-
Histone H4 (06-866; Millipore). Blots were then incu-
bated with horseradish peroxidase-conjugated secondary
antibodies (NA934; GE Healthcare Biosciences, Piscat-
away, NJ, USA) and reacted with chemiluminescence
reagents (GE Healthcare Biosciences). Relative band
intensity was quantified using ImageJ software [32].
Chromatin immunoprecipitation-qPCR
Chromatin immunoprecipitation (ChIP) was performed
using the LowCell# ChIP kit (Diagenode, Seraing, Bel-
gium), according to the manufacturer’s protocol. After
cell lysis, the chromatin was sonicated to an average size
of 500 base pairs (bp) and enriched with Protein
G-coated magnetic bead (Diagenode)-coupled antibody
against acetyl-Histone H3K9 (MAb-185-050; Diagenode),
acetyl-Histone H4K8 (pAb-103-050; Diagenode), acetyl-
Histone H4K12 (17-10121; Millipore) or mouse immuno-
globulin (Ig)G (Diagenode) at 4C overnight. Following
cross-link reversal and DNA isolation, samples were sub-
ject to qPCR as described above. The specific sequences
from immunoprecipitated and input DNA were detected
by PCR primers for promoter regions within the TNF-a
and IL-8 gene loci that are important nucleosomal bind-
ing regions as described previously [33–35]. The TNF-a
PCR primer lies within the distal upstream promoter
region of TNF-a (2195/–345) [33,34]: forward: 50-CCC
AAAAGAAATGGAGGCAAT-30, reverse: 5-AAGCATCAAG
GATACCCCTCAC-30. The IL-8 PCR primer lies within
the promoter region of IL-8 [35]: forward: 50-CAGAGA
CAGCAGAGCACAC-30, reverse: 50-ACGGCCAGCTTG
GAAGTC-30. The efficiency of the experimental ChIP for
the specified genomic locus was calculated from qPCR
data as a percentage of starting material with the same
primer set.
Data analysis
All data are presented as mean 6 standard deviation
(s.d.) unless noted otherwise. Figures contain representa-
tive data of experiments performed in triplicate. Statistical
analysis was performed with Student’s t-test to compare
data between two groups. A two-tailed P-value <005 was
considered statistically significant.
Results
Citrate’s effect on TNF-a protein production
following LPS stimulation varies by calcium
concentration
To test the ability of citrate to alter proinflammatory
cytokine responses, we utilized THP-1 cells to model
monocyte cellular responses. In standard tissue culture
medium, LPS-induced TNF-a protein production (6 h)
was augmented at low citrate concentrations and inhib-
ited at high citrate concentrations relative to controls
(Fig. 1a). To test the importance of calcium chelation in
the TNF-a response, THP-1 cells were incubated in
medium supplemented with additional calcium. In these
higher calcium conditions, the LPS-induced TNF-a
proinflammatory response is no longer inhibited at high
citrate concentrations (Fig. 1b). Instead, high levels of
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citrate augmented the TNF-a response well above citrate-
untreated control culture conditions. Of note, citrate
alone, in either normal or supplemented calcium
medium, did not alter TNF-a levels in the absence of
LPS (data not shown). To determine if the effect of citrate
can be explained by extracellular calcium chelation, THP-
1 cells were pretreated with the calcium-selective chelator
EGTA [36,37]. As can be seen in Fig. 1c,d, high concen-
trations of EGTA inhibited TNF-a levels in both standard
and supplemental calcium media. In contrast to the
effects of citrate, no augmentation effect was seen with
EGTA. This pattern of responses to citrate in medium
containing varying calcium concentrations indicates that
the effect of citrate on the TNF-a response is explained
incompletely by calcium chelation alone.
Citrate augments and inhibits TNF-a and IL-8 mRNA
production in THP-1 cells following LPS stimulation
To determine if citrate is altering the TNF-a proinflam-
matory response at the level of transcription versus trans-
lation, we characterized the levels of TNF-a mRNA
transcripts under similar experimental conditions. In
standard tissue culture medium, TNF-a mRNA produc-
tion (2 h) showed a similar pattern to what was seen at
the protein level: low concentrations of citrate augmented
the TNF-a response while higher citrate concentrations
inhibited TNF-a mRNA (Fig. 2a). In medium supple-
mented with additional calcium, citrate doubled TNF-a
mRNA production at moderate and high citrate concen-
trations, similar to what was seen with TNF-a protein
(Fig. 2b). These findings indicated that citrate may be
altering TNF-a transcription.
To determine if this response was unique to TNF-a or
if it extended to other LPS-induced proinflammatory
genes, IL-8 mRNA levels were measured following citrate
pretreatment and LPS stimulation. In both normal and
calcium-supplemented media, citrate augmented and
inhibited the IL-8 mRNA response in a manner that par-
alleled the TNF-a response (Fig. 2c,d). These data suggest
that citrate alters LPS-induced proinflammatory TNF-a
and IL-8 cytokine production by augmenting or inhibi-
ting gene transcripts.
Citrate alters transactivation of IL-8 promoter activity
As TNF-a and IL-8 gene expression is largely NF-jB-
dependent, THP-1 cells were transfected transiently with
Fig. 1. Citrate augments and inhibits tumour necrosis factor (TNF)-a protein production. Human acute monocytic leukaemia cell line (THP-1)
cells were incubated (30 min) with varying concentrations of citrate (a,b) or ethylene glycol tetraacetic acid (EGTA) (c,d) prior to stimulation
with lipopolysaccharide (LPS) (6 h). TNF-a protein production was determined by enzyme-linked immunosorbent assay (ELISA) in normal
medium (04 mM calcium, a,c) and in supplemental calcium medium (14 mM, b,d) (*<005, n.s. = not significant).
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a jB-dependent luciferase reporter construct to assess
NF-jB transcriptional activation [38]. In standard tissue
culture medium, luciferase expression (4 h) was aug-
mented at low concentrations of citrate and inhibited at
high concentrations of citrate compared to stimulated
controls (Fig. 3a). These findings are consistent with the
response pattern observed in mRNA and protein produc-
tion. In calcium-supplemented medium, luciferase expres-
sion was augmented at high concentrations of citrate
(Fig. 3b). Taken together, these data indicate citrate is
altering IL-8 cytokine transcription by modulating the
transactivation of the IL-8 promoter, in a manner
dependent on calcium concentrations.
TCA, a structural analogue of citrate, inhibits TNF-a
mRNA production following LPS stimulation
THP-1 cells were treated with TCA to assess the relative
importance of calcium chelation versus flux through ACLY
in the ability of citrate to modulate the TNF-a response to
LPS. In standard medium, high concentrations of TCA
inhibited TNF-a mRNA production (2 h) compared to
stimulated controls, a response similar to that in the pres-
ence of citrate (Fig. 4a). However, at lower concentrations
of TCA (1 mM) in standard medium, there is no augmen-
tation effect as is observed with citrate (Fig. 4a). In stark
contrast to treatment with citrate, in supplemented calcium
medium high concentrations of TCA inhibited TNF-a
mRNA production in a dose–response pattern (Fig. 4b).
Citrate is used as a metabolic substrate to augment
TNF-a production
Due to the difference in TNF-a responses with citrate
and TCA, we hypothesized that citrate may be metabo-
lized by ACLY during monocyte inflammatory responses
[13,15]. To test this hypothesis, THP-1 cells were co-
incubated with TCA and citrate prior to LPS stimulation.
In both normal and supplemented calcium media, treat-
ment of cells with TCA alone inhibits TNF-a mRNA, and
treatment with citrate alone augments TNF-a mRNA lev-
els (Fig. 4c,d). However, co-treatment with citrate and
Fig. 2. Citrate augments and inhibits proinflammatory cytokine mRNA production. Human acute monocytic leukaemia cell line (THP-1) cells
were incubated (30 min) with varying concentrations of citrate prior to stimulation with lipopolysaccharide (LPS) (2 h). mRNA was isolated and
subsequently analysed by quantitative polymerase chain reaction (qPCR). (a) Tumour necrosis factor (TNF)-a mRNA production in normal
calcium medium (04 mM). (b) TNF-a mRNA production in supplemental calcium medium (14 mM). (c) IL-8 mRNA production in normal
calcium medium (04 mM). (d) IL-8 mRNA production in supplemental calcium medium (14 mM). Data were normalized to the LPS-
stimulated sample with no citrate (*P<005, n.s. = not significant).
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TCA abrogates the ability of citrate to augment LPS-
induced TNF-a mRNA. The ability of TCA to prevent
augmentation of the inflammatory response, while main-
taining an inhibitory effect, implies that citrate’s ability to
augment inflammatory cytokine production is independ-
ent of calcium chelation and may depend instead upon
its metabolism through ACLY.
Citrate prolongs histone acetylation following LPS
stimulation
Because ACLY metabolizes citrate into acetyl CoA and
oxaloacetate, we sought to determine if citrate was
increasing the availability of acetyl donors by characteriz-
ing the global acetylation of histones H3 and H4 lysine
residues. In standard medium, preincubation with low
and high concentrations of citrate increased histone H3
and H4 acetylation at baseline compared to control cells
(Fig. 5a). In response to LPS stimulation, control cells in
standard medium showed an increase in H3 acetylation
and a slight decrease in H4 acetylation. Under these same
conditions, treatment with citrate increased both H3 and
H4 acetylation relative to control (Fig. 5a). In supple-
mented calcium medium, control cells at baseline prior to
LPS stimulation showed high levels of histone acetylation
that then decreased following LPS (Fig. 5b). Citrate-
treated cells also showed a decrease in histone H3 and H4
acetylation following LPS, although high citrate concen-
trations limited the decrease in H4 acetylation (Fig. 5b).
These data suggest that citrate can increase global levels
of histone acetylation.
Citrate increases histone acetylation at inflammatory
gene promoters in THP-1 cells
Given the ability of citrate to alter global histone acetyla-
tion, we sought to determine if citrate could alter histone
acetylation at specific inflammatory gene regions as a
means of priming these genes for transcriptional activa-
tion. Therefore, we assessed the acetylation marks at three
lysine residues on histones H3 and H4 located in the
gene promoter regions of TNF-a and IL-8 via ChIP
[33–35]. Experiments were conducted in medium supple-
mented with calcium and cells were incubated at low
citrate concentrations in order to model the steady-state
plasma calcium and citrate levels in patients on CRRT
[5]. Histone H3 lysine 9 acetylation, H4 lysine 8 acetyla-
tion and H4 lysine 12 acetylation were augmented signifi-
cantly in THP-1 cells incubated with citrate compared to
controls at both the TNF-a and IL-8 promoter regions
(Fig. 6a,b, respectively). To determine if these effects were
specific to citrate, THP-1 cells were incubated with
15 mM TCA instead of citrate. As can be seen in Fig. 6,
TCA is also able to increase histone acetylation in the
promoter regions of both TNF-a and IL-8.
Discussion
Pretreatment of THP-1 cells with citrate resulted in a
dichotomous response to LPS that depended upon both
citrate and calcium concentrations. When calcium avail-
ability is limiting due to sequestration by citrate chela-
tion, as seen within the CRRT circuit, THP-1 monocytes’
TNF-a mRNA and protein production is inhibited. This
result is expected, given the calcium-dependent nature of
this proinflammatory signalling pathway [22–24], and is
also seen with experiments using the extracellular calcium
chelator EGTA (see Fig. 1). However, when calcium
Fig. 3. Citrate affects transactivation of the interleukin (IL)-8
promoter. Human acute monocytic leukaemia cell line (THP-1) cells
were transiently transfected with a 2162/144 hIL-8 luc plasmid.
Cells were stimulated with lipopolysaccharide (LPS) for 4 h
following preincubation with varying concentrations of citrate in
either (a) normal medium (04 mM calcium) or (b) supplemental
calcium medium (14 mM). Luciferase activity was measured using a
Luciferase Assay System (Promega) and a Spectramax M3
spectrophotometer (Molecular Devices). Data were normalized to
the LPS-stimulated sample with no citrate (*P<005, n.s. = not
significant).
Citrate modulates monocyte inflammatory responses
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availability is not limiting, as can be seen either with low
citrate concentrations or with calcium concentrations
similar to levels achieved within a patient on CRRT
(1–14 mM), citrate augmented TNF-a mRNA and pro-
tein production following LPS stimulation. Under these
same conditions, IL-8 mRNA transcripts followed a simi-
lar trend to that of TNF-a mRNA. This same response
was also observed with an IL-8-luc reporter construct,
indicating that citrate is modulating monocyte proinflam-
matory TNF-a and IL-8 responses via transactivation of
NF-jB and/or activator protein-1 (AP-1). We therefore
sought to examine how exogenous citrate may be utilized
in the cell to promote an increase in cytokine production.
With citrate being an important metabolic substrate, we
hypothesized that the metabolism of citrate could con-
tribute to these altered cellular responses.
Citrate metabolism by ATP-citrate lyase
Several factors point to the importance of ACLY in the
metabolism of citrate during the inflammatory response.
Its activity is increased by the presence of citrate, it is up-
regulated following LPS stimulation, and inhibition of
ACLY decreases the production of key inflammatory
mediators such as nitric oxide, reactive oxygen species
and prostaglandin E2 [14,39]. We tested the importance
of ACLY in our system through the use of TCA, a com-
petitive inhibitor of ACLY that has an inhibition constant
of 1 mM [12]. TCA is a structural analogue of citrate
that differs due only to the lack of a hydroxyl group at
the 20 carbon. This minor structural change decreases the
ability of TCA to chelate calcium by 40-fold relative to
citrate (citrate has a calcium dissociation constant of
Fig. 4. Tricarballylic acid (TCA) inhibits monocyte inflammatory responses. (a,b) Human acute monocytic leukaemia cell line (THP-1) cells were
stimulated with lipopolysaccharide (LPS) (2 h) following preincubation with varying concentrations of TCA to determine tumour necrosis factor
(TNF)-a mRNA production in (a) normal calcium (04 mM) or (b) supplemental calcium (14 mM) media. (c,d) THP-1 cells were pretreated
(05 h) with TCA (15 mM) alone, citrate (1 mM) alone, or co-incubated with citrate and TCA prior to LPS stimulation to determine TNF-a
mRNA production (2 h) in (c) normal calcium (04 mM) or (d) supplemental calcium (14 mM) media. Data were normalized to the LPS-
stimulated sample with no citrate or TCA (*P<005, n.s. = not significant).
M. J. Ashbrook et al.
526 VC 2015 British Society for Immunology, Clinical and Experimental Immunology, 180: 520–530
04 versus 15 mM for TCA) [40]. We found that TCA is
able to both inhibit LPS-induced TNF-a mRNA tran-
scripts and block the ability of citrate to augment TNF-a.
The ability of TCA to inhibit TNF-a at concentrations
above the KI for ACLY but below its calcium chelation
constant implies that ACLY inhibition may be more
important than calcium chelation in the ability of TCA to
modulate the TNF-a LPS inflammatory response. These
findings support our hypothesis that citrate metabolism
by ACLY is essential for its ability to augment LPS-
induced proinflammatory responses, and support the
importance of ACLY in LPS-triggered inflammation.
ACLY generates both acetyl-CoA and oxaloacetate and
therefore it is possible that either metabolite may contrib-
ute to augmented LPS inflammatory responses due to
exogenously added citrate. During the inflammatory
response, oxaloacetate has been shown to be important in
the generation of NADPH which is subsequently utilized
for reactive oxygen species production [13,14]. Similarly,
acetyl-CoA can be used to generate prostaglandins [14].
However, both these observations occur after the initial
inflammatory insult in accordance with citrate being
actively shuttled out of the mitochondria. We therefore
sought a mechanism on how external citrate added to the
system may contribute to augmented gene activation.
Signalling pathways leading to transcriptional activa-
tion have been linked with metabolism [41]. Protein
modifications leading to transcriptional activation, such
as acetylation, are generated from metabolites [42]. In
mammalian cells, acetyl-CoA can be generated by ACLY
or acetyl-CoA synthetase 1 for use in protein acetylation
[15]. The acetyl-CoA produced by ACLY is derived from
the conversion of glucose into citrate which is then
cleaved by ACLY to form oxaloacetate and acetyl-CoA
[43]. Cleavage of citrate to acetyl-CoA via ACLY is the
preferred pathway for acetyl-CoA production under high
nutrient conditions [16]. It has been shown that ACLY
localizes to the nucleus and that nutrient availability
alters histone acetylation, suggesting a link between cellu-
lar metabolism and histone acetylation via ACLY [15].
Acetylation of histones allows for protein access to DNA
binding sites and increases the transcription of target
Fig. 5. Citrate modulates global histone acetylation. Changes in
histone H3 and H4 global acetylation were determined by Western
blot in acid-extracted lysates of human acute monocytic leukaemia
cell line (THP-1) cells. Cells were preincubated with varying
concentrations of citrate (0, 1, 6 mM) prior to stimulation with
lipopolysaccharide (LPS) (0–90 min) in (a) normal calcium
(04 mM) or (b) supplemental calcium (14 mM) media. Relative
band intensity is represented by the numbers below the Western
blots with the no citrate time zero condition assigned a relative
value of 100.
Fig. 6. Citrate increases histone lysine acetylation at inflammatory gene promoters. Chromatin immunoprecipitation (ChIP) assays were
performed in a human acute monocytic leukaemia cell line (THP-1) with antibodies against histone H3K9ac, H4K8ac and H4K12ac following
preincubation with citrate (1 mM) or tricarballylic acid (TCA) (15 mM) in supplemental calcium medium (14 mM). The efficiency of the
experimental ChIP for the specified genomic locus was calculated from quantitative polymerase chain reaction (qPCR) data as a percentage of
starting material with the same primer set (% input) and then normalized to control conditions. (a) Tumour necrosis factor (TNF)-a. (b)
Interleukin (IL)-8. Error bars represent standard deviation calculated from at least three separate experiments. (*P<001, n.s. = not significant).
Citrate modulates monocyte inflammatory responses
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genes [19]. We hypothesized that citrate increases the
availability of acetyl groups by its conversion into acetyl-
CoA by ACLY in the nucleus. Having an increase in acetyl
groups at active gene locations may provide a continuous
pool of substrate for acetylation, thereby promoting
enhanced transcription by facilitating acetylation of his-
tone and non-histone proteins and insulating from meta-
bolic changes [17]. We showed that citrate prolonged the
global acetylation of histones H3 and H4 treated with
LPS, thereby potentially linking citrate to enhanced gene
transcription via acetyl group formation. Using ChIP
analyses, we showed that treatment of THP-1 cells with
citrate could induce chromatin remodelling at TNF-a
and IL-8 gene promoter regions. However, treatment with
TCA was also able to increase histone acetylation at these
gene promoter regions. As a competitive inhibitor of
ACLY, TCA should decrease the availability of acetyl-CoA.
This result is not consistent with the hypothesis that his-
tone acetylation can be increased by simply providing
additional acetyl-CoA substrate. Instead, these findings
suggest that citrate and TCA may alter histone acetylation
via an alternative pathway, such as changes to the activa-
tion of histone acetyltransferases.
Clinical implications
The ability of citrate to modulate monocyte inflammatory
responses has many potential clinical implications, given
citrate’s broad usage as an anti-coagulant and its impor-
tance in biological pathways. It is known that trauma
patients who receive massive blood transfusions (and
hence large amounts of citrate) have increased incidence
of developing sepsis and systemic inflammatory response
syndrome [44,45]. When used as a regional anti-
coagulant for CRRT, citrate has many advantages includ-
ing increased circuit lifetimes and fewer bleeding compli-
cations [8,9]. However, it has long been recognized that
some patients, especially those with liver dysfunction, are
at risk of developing increased systemic citrate concentra-
tions [46]. Recently a prospective study by Link et al.
found that CRRT patients with total to ionized calcium
ratios >24 (reflective of increased citrate concentrations)
had a 335-fold increased risk of mortality [47]. We
speculate that citrate’s ability to modulate inflammatory
responses could be playing a central role in increasing
the development of SIRS in trauma patients and increas-
ing mortality in CRRT patients with elevated citrate
levels.
Outside its use as an anti-coagulant, high concentra-
tions of citric acid are found in citrus fruits and citrate
salts are used to alkalinize the urine in the treatment of
kidney stones [48,49]. It is tempting to speculate if oral
and dietary sources of citrate could alter inflammatory
responses. Studies of the renal handling of citrate demon-
strate that the increase in urinary citrate does not result
directly from an increase in plasma citrate levels. Instead,
the kidney increases urinary citrate excretion in response
to a metabolic alkalosis, which can be induced by bicar-
bonate infusion or from the metabolism of citrate into
bicarbonate [50]. These studies imply that, when taken
orally, citrate is subject to extensive metabolism by the
liver and that oral intake of citrate does not result in ele-
vated plasma levels of citrate. In contrast, when citrate is
used as an anti-coagulant, it is infused directly into the
systemic circulation. Even then, elevated citrate levels are
seen typically only in patients who receive massive blood
product transfusions, have liver dysfunction or receive
continuous citrate infusions with CRRT [46,51,52]. As
such, we feel it is unlikely that citrate in food or other
sources could produce elevated plasma levels of citrate
such that it would impact monocyte inflammatory
responses.
Lastly, the proinflammatory state caused by diabetes
has been attributed to the effects of hyperglycaemia on
modulating immune cell responses [53,54]. Monocytes
in diabetic conditions show an altered phenotype lead-
ing to an increase in proinflammatory cytokine produc-
tion [55,56]. In a hyperglycaemic state, monocytes show
an increase in NF-jB localization, histone acetylation
and histone acetyltransferase activity localized at inflam-
matory genes leading to increased cytokine production
[57,58]. However, links between hyperglycaemia,
increased protein acetylation and the inflammatory sig-
nal cascade have not been defined explicitly. Metabolism
of glucose into citrate may provide a link in understand-
ing the augmented inflammatory state seen in patients
with diabetes.
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